Today: 19 May 2026
Browse Category

AMS:AEG 10 December 2025

Top US Stock Losers Today (December 10, 2025): Why Polestar, AeroVironment, Aegon and Other Names Are Sinking

Top US Stock Losers Today (December 10, 2025): Why Polestar, AeroVironment, Aegon and Other Names Are Sinking

Polestar shares plunged 23.5% intraday Wednesday, leading US stock decliners, as funding concerns deepened. Major indexes were flat ahead of the Federal Reserve’s rate decision, with the Dow near 47,650 and S&P 500 around 6,841. High-beta growth stocks, EV names, and resource plays saw sharp drops, while most S&P 500 losses remained modest. Traders awaited signals from Fed Chair Jerome Powell on inflation and policy.
10 December 2025
······
Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Top Pre‑Market Losers Today (December 10, 2025): AFJK, CBRL, DNLI & AEG Lead Early Declines Before the Bell

Aimei Health Technology plunged nearly 50% in pre-market trading after extending its business-combination deadline. Lion Group Holding and JX Luxventure Group each dropped over 35%. Broader U.S. stock futures showed little movement as investors awaited the Federal Reserve’s rate decision later today. Cracker Barrel and Denali Therapeutics also traded lower on fresh news and analyst calls.
10 December 2025
····

Stock Market Today

  • SEC Set to Release Innovation Exemption for $1.4 Billion Tokenized Stock Market
    May 19, 2026, 1:42 AM EDT. The U.S. Securities and Exchange Commission (SEC) is preparing to announce an "innovation exemption" allowing trading of tokenized stocks-digital versions of public company shares-on decentralized platforms. This represents a pivotal regulatory shift, enabling tokens to track share prices without corporate backing or traditional shareholder rights like voting or dividends. The tokenized stock market has surged nearly 30% to $1.4 billion in distributed value across 2,246 assets, with monthly transfer volume hitting $3.24 billion and holders growing 25% to 265,000. Industry players such as Ondo and xStocks dominate the space, holding 59.77% and 27.38% market shares respectively. The move aligns with major firms like DTCC, Nasdaq, and NYSE planning on-chain settlements and tokenized equity rollouts by 2026.

Latest articles

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

Nasdaq gives up after-hours gains as oil and yields weigh on Wall Street rally

19 May 2026
Dominion Energy shares jumped 9.4% after agreeing to an all-stock merger with NextEra Energy, whose shares fell 4.6%. The S&P 500 slipped 0.1% and the Nasdaq dropped 0.5% as investors sold technology stocks amid rising Treasury yields and oil prices. Nvidia fell 1.4% ahead of earnings. U.S. crude settled at $107.37, and the 10-year Treasury yield reached 4.59%.
XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

XP Shares Slip Post-Q1, Buyback Fails to Sway Investors

19 May 2026
XP Inc.’s U.S.-listed shares fell 3.78% in after-hours trading Monday after reporting higher Q1 profit but weaker net inflows and a lower retail take rate. Net income rose 7% to 1.32 billion reais, but net inflow dropped to 14 billion reais from 24 billion a year earlier. The company declared a $0.20 dividend and announced a new CFO, Gustavo Alejo Viviani, starting August 3.
LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

LiveRamp Rallies 27% After Publicis $2.5 Billion Cash Bid

19 May 2026
Publicis Groupe agreed to buy LiveRamp Holdings for $38.50 a share in cash, valuing the U.S. data-collaboration firm at $2.546 billion. LiveRamp stock jumped to $37.77 on the news, while the broader market fell. LiveRamp reported fiscal Q4 revenue of $206 million, up 9% from a year earlier. Publicis said the deal will boost its adjusted earnings per share from the first year after closing.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Go toTop